27 September Seminars

09:30 - 10:00

Academy of Pharmaceutical Sciences

Speaker

  • Dr. Sudipto Das Star Research Lecturer - Pharmacy and Biomolecular Sciences, RCSI
09:30 - 10:30

Bridging the Skills Gap in the Pharma Industry

Speakers

  • Amy Dillon Skills Enhancement Tutor - Edinburgh Napier University
  • View full profile for Dr David MincherDr David Mincher Senior Lecturer, School of Applied Sciences - Edinburgh Napier University
10:00 - 10:30

UKICRS_2

10:30 - 11:30

Break and Exhibition

11:30 - 12:00

Multifaceted Functionality of Micro- and Nano-Systems in Health

Speaker

11:30 - 12:00

The Value of the EXCiPACT Certification Scheme

Speaker

12:00 - 12:30

Academy of Pharmaceutical Sciences – Delivering Meaningful Impact From University Research – A Nanotechnology Tale!

Speaker

  • Dr Jonny Coulter Reader, School of Pharmacy, Material and Advanced Technologies for Healthcare - Queens University Belfast
12:00 - 12:30

The IPEC – PQG GMP Guide

Speaker

12:30 - 14:00

Break & Exhibition

14:00 - 14:20

Enabling Decarbonisation of the Pharmaceutical Supply Chain

Sustainability is integral to everything we do. From the raw materials we source and the way we use them, to the ingredients we create, we believe in being a responsible company
By 2030 we will be the most sustainable supplier of innovative ingredients, helping to provide solutions to some of the world's biggest challenges.

Excipient manufacturers are making steps towards strengthening and ensuring a sustainable pharmaceutical supply chain through reducing use of fossil fuel energy sources, improving energy efficiency of manufacturing processes and purchasing raw materials from suppliers aligned to the net zero journey.

The transparency and consistency of reporting sustainability throughout the supply chain is imperative to its success.

Speaker

14:00 - 14:30

Strategic API Sourcing – How to Choose a Source That is Right for You

Speaker

14:20 - 14:40

Surfactants in Bioformulation: Are We at the End or the Beginning of a Journey?

This presentation will review and highlight the importance of surfactants in the production and formulation of biological actives for the biopharma industry. It will introduce and explain BASFs approach to this key class of functional materials for the biopharma industry, and the impact of excipients on biologics formulations. It will also cover the effect on stability under different stress conditions and also discuss alternative surfactants polysorbate 20 and 80: Poloxamer 188 (Kolliphor® P 188 Bio), Kolliphor® HS 15, Kolliphor® ELP).

Speaker

14:20 - 14:40

Tableting Oily APIs

Speaker

14:40 - 15:00

A Convenient Formulation of Orodispersible Mini-tablets for Pediatric Administration

Orodispersible mini-tablets (ODMT) are a beneficial dosage form for pediatrics and geriatrics. Furthermore they can be used for flexible dosing in broader Patient Groups. A recent study to determine the suitability of agglomerated Isomalt, a Disaccharide alcohol, as a direct compression filler-binder for producing ODMT with hydrochlorothiazide and enalapril maleate, as model commonly used pediatric drugs, is described.

Speaker

14:40 - 15:00

Novel Excipients For Parenteral Formulations

Excipients are typically the major components in a drug product. Many formulations contain only a small percentage of the active drug molecules. Pharmaceutical excipients or additives are compounds added to the finished drug products to serve a specific function.
Injectable products require a unique formulation strategy. The formulated product must be sterile, pyrogen-free, and, in the case of solution, free of particulate matter. No coloring agent may be added solely for the purpose of coloring the parenteral preparation. The formulation should preferably be isotonic, and depending on the route of administration, certain excipients are not allowed. The injected drug by-passes natural defense barriers; hence, for any given drug, the risk of an adverse event may be greater or the effects difficult to reverse if administered as an injection rather than a non-parenteral route. For this reason ultra-high purity grades of excipients are available for parenteral administration. Sterility requirements demand that an excipient is able to withstand terminal sterilization or aseptic processing. These factors limit the choice of excipients available in the market. With the new products for Clariant the choice of excipients have increased for parenteral formulations and in the presentation we will discuss the new product range.

Speaker

  • Shilpa Mistry Head of Pharma, UK and Ireland - Chemlink Specialities Ltd
15:00 - 16:00

Break & Exhibition

16:00 - 16:20

Hygienic Seals – Insights Into Safe Pharmaceutical Production

Bio-films are difficult to remove, are often resistant to normal sanitation procedures, and can result in detrimental process effects. Even when a surface appears to be clean the presence of bio-films is a potential hazard that must be eliminated and prevented from reoccurring. The presentation gives insights into avoiding bio-film build up, and the benefits of hygienic seals in safe pharmaceutical production in line with European Hygienic Design Group guidelines.

Speaker

  • Neil Firth Business Development Manager - Garlock GB Ltd
16:00 - 16:20

What is the Right Entrance Solution For My Cleanroom? High Speed Doors or Automatic Doors?

A critical decision to secure the purity and safety of goods produced in controlled environments is how to seal off a Clean Room or Controlled Atmospheric Area.

This technology insight will cover door solutions for clean rooms including those with conveyor integration and robotics solutions. It includes the most modern touchless opening technologies to help the listener holistically evaluate the complete solution.

A discussion around Future Proofing Clean Rooms with the potential of Connected Door Solutions, integration per BUS Systems or with Building Management Systems, rounds off the digital potential of doors in a connected factory.

Assa Abloy is the global leader in the research, design, manufacture and support of a range of Automated Industrial and Commercial Doors.

Employing a team of over 50,000  globally, the customer is at the centre of everything we do.

Speakers

16:20 - 16:40

Benefits of Dry Granulation using Roller Compaction

In today's competitive Pharmaceutical markets, finding production cost advantages is essential. Dry granulation has in the past only been considered beneficial for heat or moisture sensitive products, however with the latest Roller Compactor technologies, this process can be used for a wide range of products.
The presentation will explain the principle of Dry granulation and compare it the more common Wet Granulation process.

Speaker

  • Fraser Gow International Sales Manager - Alexanderwerk
16:20 - 16:40

Regulatory Guidance on the Life Cycle Approach to Container Closure Integrity Testing

This presentation will look at the path of regulatory guidance over the last decade, in the context of container closure integrity inspection for pharmaceutical product packaging and help explain what this means across the manufacturing life-cycle.
We will cover why different approaches and justifications need to be considered for different stages of product development and manufacture and look at emerging technologies and where they fit across these various stages.

Speaker